Identification and enrichment of cell subpopulations

Patent metadata

Field	Value
Publication number	US-9778264-B2
Application number	US-201414454107-A
Country	US
Kind code	B2
Filing date	Aug 7, 2014
Priority date	Sep 3, 2010
Publication date	Oct 3, 2017
Grant date	Oct 3, 2017

Abstract

Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.

First claim

The invention claimed is:

1. A method of producing an animal model comprising implanting a subject animal with an enriched tumorigenic cell population comprising tumorigenic cells and an anti-CD46 antibody associated with a detectable agent, wherein the tumorigenic cells have a marker phenotype comprising CD46 hi , and wherein the detectable agent comprises a fluorescent tag.

2. The method of claim 1 , wherein the enriched tumorigenic cell population is derived from a solid tumor obtained from a subject suffering from a neoplastic disorder selected from the group consisting of adrenal cancer, bladder cancer, cervical cancer, endometrial cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, head & neck cancer, and skin cancer.

3. The method of claim 2 , wherein the subject animal is an immunodeficient mouse.

4. The method of claim 3 , wherein the immunodeficient mouse is selected from the group consisting of a nude mouse, a SCID mouse, a NOD/SCID mouse and a Beige/SCID mouse.

5. The method of claim 1 , wherein the enriched tumorigenic cell population further comprises an anti-CD324 antibody associated with a second detectable agent and wherein the tumorigenic cells have a marker phenotype comprising CD46 hi CD324 + .

6. The method of claim 5 , wherein the tumorigenic cells have a marker phenotype comprising CD46 hi CD324 + CD66c − .

7. The method of claim 1 , wherein the enriched tumorigenic cell population is derived from a tumor that has been passaged through a non-human mammal.

8. A method of producing an animal model comprising implanting a subject animal with an enriched tumorigenic cell population comprising tumorigenic cells having a marker phenotype comprising CD46 hi CD324 + , an anti-CD46 antibody associated with a first detectable agent, and an anti-CD324 antibody associated with a second detectable agent, wherein the detectable agent comprises a fluorescent tag.

9. The method of claim 8 , wherein the subject animal is an immunodeficient mouse.

10. The method of claim 9 , wherein the immunodeficient mouse is selected from the group consisting of a nude mouse, a SCID mouse, a NOD/SCID mouse and a Beige/SCID mouse.

11. The method of claim 8 , wherein the enriched tumorigenic cell population is derived from a solid tumor obtained from a subject suffering from a neoplastic disorder selected from the group consisting of adrenal cancer, bladder cancer, cervical cancer, endometrial cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, head & neck cancer, and skin cancer.

12. The method of claim 8 , wherein the enriched tumorigenic cell population is derived from a tumor that has been passaged through a non-human mammal.

13. The method of claim 8 , wherein the tumorigenic cells have a marker phenotype comprising CD46 hi CD324 + CD66c − .

14. A method of producing an immunodeficient mouse animal model comprising implanting an immunodeficient mouse with an enriched tumorigenic cell population comprising tumorigenic cells having a marker phenotype comprising CD46 hi and an anti-CD46 antibody associated with a detectable agent, wherein the detectable agent comprises a fluorescent tag.

15. The method of claim 14 , wherein the immunodeficient mouse is selected from the group consisting of a nude mouse, a SCID mouse, a NOD/SCID mouse and a Beige/SCID mouse.

16. The method of claim 14 , wherein the enriched tumorigenic cell population is derived from a solid tumor obtained from a subject suffering from a neoplastic disorder selected from the group consisting of adrenal cancer, bladder cancer, cervical cancer, endometrial cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, head & neck cancer, and skin cancer.

17. The method of claim 14 , wherein the enriched tumorigenic cell population is derived from a tumor that has been passaged through a non-human mammal.

18. The method of claim 14 , wherein the enriched tumorigenic cell population further comprises an anti-CD324 antibody associated with a second detectable agent and wherein the tumorigenic cells have a marker phenotype comprising CD46 hi CD324 + .

19. The method of claim 18 , wherein the tumorigenic cells have a marker phenotype comprising CD46 hi CD324 + CD66c − .

20. A method of producing an immunodeficient mouse animal model comprising implanting an immunodeficient mouse with an enriched tumorigenic cell population comprising tumorigenic cells having a marker phenotype comprising CD46 hi CD324 + , an anti-CD46 antibody associated with a first detectable agent, and an anti-CD324 antibody associated with a second detectable agent, wherein the detectable agent comprises a fluorescent tag.

21. The method of claim 20 , wherein the immunodeficient mouse is selected from the group consisting of a nude mouse, a SCID mouse, a NOD/SCID mouse and a Beige/SCID mouse.

22. The method of claim 20 , wherein the enriched tumorigenic cell population is derived from a solid tumor obtained from a subject suffering from a neoplastic disorder selected from the group consisting of adrenal cancer, bladder cancer, cervical cancer, endometrial cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, head & neck cancer, and skin cancer.

23. The method of claim 20 , wherein the enriched tumorigenic cell population is derived from a tumor that has been passaged through a non-human mammal.

24. The method of claim 20 , wherein the tumorigenic cells have a marker phenotype comprising CD46 hi CD324 + CD66c − .

Assignees

• Stem Centrx Inc
• Abbvie Stemcentrx Llc

Inventors

• Dylla Scott J
• Santaguida Marianne
• Anderson Wade C
• Liu Bob Y
• Williams Samuel A

Classifications

• G01N33/5759 Primary

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C12N5/0693

  Tumour cells; Cancer cells · CPC title

• A61K39/0011 Primary

  Cancer antigens · CPC title

• G01N33/57492 Primary

  Physics · mapped topic